Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema dose comparison versus semaglutide in adults with obesity with or without type 2 diabetes
2025-522488-14-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 19
01
Overview
Phase 3, randomised trial of CagriSema and semaglutide in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight. Planned start Jul 2026; status: authorised.
02
Drugs
CagriSemasemaglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-522488-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522488-14-00.